

R Brett Mcqueen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4455604/publications.pdf>

Version: 2024-02-01

35
papers

957
citations

623188

14
h-index

454577

30
g-index

36
all docs

36
docs citations

36
times ranked

1418
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1071-1081.e9.	2.0	229
2	Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 227-236.	0.9	102
3	Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. <i>Pharmacoeconomics</i> , 2018, 36, 957-971.	1.7	72
4	Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. <i>JAMA Network Open</i> , 2019, 2, e190035.	2.8	72
5	Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. <i>JAMA Pediatrics</i> , 2018, 172, 1161.	3.3	69
6	Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 220-225.	0.5	67
7	Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. <i>Cost Effectiveness and Resource Allocation</i> , 2011, 9, 13.	0.6	59
8	Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. <i>Diabetes Care</i> , 2020, 43, 1496-1503.	4.3	53
9	Economic burden of comorbid chronic kidney disease and diabetes. <i>Journal of Medical Economics</i> , 2017, 20, 585-591.	1.0	39
10	The "in Cost-Effectiveness Analyses. A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. <i>Annals of the American Thoracic Society</i> , 2014, 11, S105-S111.	1.5	27
11	CGM Metrics Predict Imminent Progression to Type 1 Diabetes: Autoimmunity Screening for Kids (ASK) Study. <i>Diabetes Care</i> , 2022, 45, 365-371.	4.3	25
12	Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications. <i>Journal of Clinical Oncology</i> , 2020, 38, 359-366.	0.8	17
13	Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 366-377.	1.3	16
14	Association Between Glycated Hemoglobin and Health Utility for Type 1 Diabetes. <i>Patient</i> , 2014, 7, 197-205.	1.1	14
15	Frequency of Continuous Glucose Monitoring use and Change in Hemoglobin A1C for Adults With Type 1 Diabetes in a Clinical Practice Setting. <i>Endocrine Practice</i> , 2014, 20, 1007-1015.	1.1	12
16	Increased Relapse Activity for Multiple Sclerosis Natalizumab Users Who Become Nonpersistent: A Retrospective Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 210-218.	0.5	8
17	Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. <i>JAMA Pediatrics</i> , 2018, 172, 409.	3.3	8
18	Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. <i>Pharmacoeconomics</i> , 2019, 37, 1321-1327.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. <i>American Journal of Managed Care</i> , 2013, 19, 278-85.	0.8	8
20	Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 80-87.	0.5	7
21	Patient and Payer Preferences for Additional Value Criteria. <i>Frontiers in Pharmacology</i> , 2021, 12, 690021.	1.6	7
22	A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. <i>Pharmacoeconomics</i> , 2020, 38, 1201-1218.	1.7	5
23	The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 782-785.	0.5	5
24	Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment. <i>Pharmacoeconomics</i> , 2021, 39, 379-382.	1.7	5
25	Identifying Sepsis From Foodborne Hospitalization: Incidence and Hospitalization Cost by Pathogen. <i>Clinical Infectious Diseases</i> , 2022, 75, 857-866.	2.9	5
26	Incorporating real-world clinical practice in multiple sclerosis economic evaluations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 869-872.	0.7	4
27	Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement. <i>Pharmacoeconomics - Open</i> , 2021, 5, 449-458.	0.9	4
28	Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 757-759.	1.0	3
29	Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". <i>Pharmacoeconomics</i> , 2019, 37, 963-964.	1.7	3
30	Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies. <i>Pharmacoeconomics</i> , 2021, 39, 1101-1107.	1.7	2
31	Achieving high value care for all and the perverse incentives of 340B price agreements. <i>Neurology: Clinical Practice</i> , 2018, 8, 148-152.	0.8	1
32	The effectiveness and value of tezepelumab for severe asthma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 577-580.	0.5	1
33	Capsule Commentary on Duru et al., Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP). <i>Journal of General Internal Medicine</i> , 2015, 30, 1697-1697.	1.3	0
34	MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
35	What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society?. <i>Pharmacoeconomics</i> , 2020, 38, 733-735.	1.7	0